Adaptate gains access to Iontas’ platform to select antibodies with optimal biophysical properties for the development of gamma delta T-cell modulating therapeutics.
Researchers have discovered a virus that is unable to replicate in humans and is ‘tolerant to genetic manipulation’ that could be used to protect humans from dangerous infectious diseases.
The abundance of data made available by continuous bioprocessing allows for more control over the process and can thereby improve the quality of the product, says Pall executive.
Gavi establishes an Ebola vaccine program for the next five years, with a stockpile of vaccines created to be made available to low- and middle-income countries free of charge.
WuXi Biologics furthers its manufacturing presence in Ireland with a manufacturing facility for its vaccines subsidiary, which will be able to produce both drug substance and drug product.
GE to set up its FlexFactory platform for antibody manufacturing at Akeso’s facility in Guangzhou, aiming to optimize the latter’s biologics production.
Solid Biosciences announces that its gene therapy for DMD has been placed under clinical hold again, after a patient experienced a serious adverse event.
Samsung continues an agreement formerly signed with Glenmark to manufacture Ichnos’ mAb treatment candidate for atopic dermatitis, as the product enters Phase III clinical trials.
Gilead’s continued investment in cell therapy manufacturing capabilities, at a time when sales at the nascent business unit are flatlining, was called into question by investors.
NIH and the Gates Foundation have set themselves the goal of bringing curative gene therapies to clinical trials in the US and Africa in the next seven to 10 years.
GE Healthcare opens lab space to provide developers with access to protein and cell analysis technologies to encourage networking and partnering on R&D services.
Early dialogue with patients is ‘critical’ to design efficient clinical development programs for ATMPs and avoid ‘data gaps’, an executive from ARM says.
Alkermes to work collaboratively with the Fred Hutchinson Cancer Research Center on the clinical development of a drug candidate as a combination treatment alongside Keytruda.
Ichnos will launch with a portfolio of five clinical stage assets, a proprietary platform, as well as a biologics manufacturing facility and 350 employees.
Sanofi opens its Massachusetts, US-based facility that will use digital technology for continuous biologic production, with similar plants planned in Canada, Brazil, Ireland, France, and Belgium.
Through funding by Novo Nordisk and the NIH, researchers from MIT have come up with a microneedle containing capsule able to release drug substance into the bloodstream.
Novo Nordisk partners with bluebird on a three-year research arrangement looking to discover gene therapy candidates for the treatment of genetic diseases, including hemophilia.
N4 Pharma creates DNA and RNA transfection technology using silica nanoparticles with an irregular surface, which traps and protects nucleic acid during its journey to cells.
GSK taps Lyell’s technology to delay ‘exhaustion’ of T cells and will explore creating a new platform to develop cell and gene therapies for rare cancers.
Merck extends its partnership with 4D Pharma to discover and develop LBP vaccines for three undisclosed indications, adding to their Keytruda partnership.
US FDA approves AstraZeneca’s at-home autoinjector for administration of an add-on treatment for severe asthma, matching the indication of GSK’s rival product, Nucala.
J&J announces the opening of its manufacturing building in Cork, Ireland, which expands the production capacity of the biopharmaceutical supply chain facility.
The news most interesting to our readers were those featuring collaborations, whether in the production of an Ebola vaccine, biosimilars entering new markets or creating new manufacturing modalities.
